The safety and efficacy of cannabinoids for the treatment of mental health and substance use disorders: protocol for a systematic review and meta-analysis
Abstract There has been a global increase in the use of cannabinoids as a treatment for mental health (MH) and substance use disorders (SUD). In 2016, an Australian government-funded review found that although medicinal cannabinoids accounted for a small reduction in MH symptoms, the results varied...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Systematic Reviews |
| Online Access: | https://doi.org/10.1186/s13643-024-02657-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585995925585920 |
|---|---|
| author | Jack Wilson Andrew Langcake Zachary Bryant Tom P. Freeman Janni Leung Gary C. K. Chan Amir Englund Myfanwy Graham Emily Stockings |
| author_facet | Jack Wilson Andrew Langcake Zachary Bryant Tom P. Freeman Janni Leung Gary C. K. Chan Amir Englund Myfanwy Graham Emily Stockings |
| author_sort | Jack Wilson |
| collection | DOAJ |
| description | Abstract There has been a global increase in the use of cannabinoids as a treatment for mental health (MH) and substance use disorders (SUD). In 2016, an Australian government-funded review found that although medicinal cannabinoids accounted for a small reduction in MH symptoms, the results varied according to study design. There has since been a rise in randomised controlled trials (RCTs) aiming to examine the efficacy of cannabinoids for the treatment of MH and SUD. Therefore, the current systematic review will (a) identify all RCTs examining the efficacy of cannabinoids in treating MH and SUD, (b) provide a quantitative or narrative synthesis of the evidence examining efficacy, and (c) synthesise adverse event data to examine evidence of harm. Electronic databases (Ovid MEDLINE, PsychINFO, Cochrane Central Register of Controlled Clinical Trials, Cochrane Database of Systematic Reviews, and Embase) were searched from 1980 to 24 May 2023. The study adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Guidelines. Articles will be screened to capture peer-reviewed RCTs evaluating the efficacy of plant-based and pharmaceutical cannabinoids in reducing or treating MH and SUD among people of any age. The Cochrane risk of bias tool 2.0 will be used to assess bias, while the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) tool will be used to assess the quality of evidence for each outcome. Study findings will be disseminated through published manuscripts, conferences, and health policy guidelines. Systematic review registration PROSPERO CRD42023392718. |
| format | Article |
| id | doaj-art-769ea36d0bc74619a21ea81c2690558d |
| institution | Kabale University |
| issn | 2046-4053 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Systematic Reviews |
| spelling | doaj-art-769ea36d0bc74619a21ea81c2690558d2025-01-26T12:17:32ZengBMCSystematic Reviews2046-40532025-01-0114111210.1186/s13643-024-02657-3The safety and efficacy of cannabinoids for the treatment of mental health and substance use disorders: protocol for a systematic review and meta-analysisJack Wilson0Andrew Langcake1Zachary Bryant2Tom P. Freeman3Janni Leung4Gary C. K. Chan5Amir Englund6Myfanwy Graham7Emily Stockings8The Matilda Centre for Research in Mental Health and Substance Use, Level 6 Jane Foss Russell Building, The University of SydneyThe Matilda Centre for Research in Mental Health and Substance Use, Level 6 Jane Foss Russell Building, The University of SydneyThe Matilda Centre for Research in Mental Health and Substance Use, Level 6 Jane Foss Russell Building, The University of SydneyAddiction and Mental Health Group (AIM), University of BathNational Centre for Youth Substance Use Research, The University of QueenslandNational Centre for Youth Substance Use Research, The University of QueenslandNational Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College LondonAustralian Centre for Cannabinoid Clinical and Research Excellence, University of NewcastleThe Matilda Centre for Research in Mental Health and Substance Use, Level 6 Jane Foss Russell Building, The University of SydneyAbstract There has been a global increase in the use of cannabinoids as a treatment for mental health (MH) and substance use disorders (SUD). In 2016, an Australian government-funded review found that although medicinal cannabinoids accounted for a small reduction in MH symptoms, the results varied according to study design. There has since been a rise in randomised controlled trials (RCTs) aiming to examine the efficacy of cannabinoids for the treatment of MH and SUD. Therefore, the current systematic review will (a) identify all RCTs examining the efficacy of cannabinoids in treating MH and SUD, (b) provide a quantitative or narrative synthesis of the evidence examining efficacy, and (c) synthesise adverse event data to examine evidence of harm. Electronic databases (Ovid MEDLINE, PsychINFO, Cochrane Central Register of Controlled Clinical Trials, Cochrane Database of Systematic Reviews, and Embase) were searched from 1980 to 24 May 2023. The study adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Guidelines. Articles will be screened to capture peer-reviewed RCTs evaluating the efficacy of plant-based and pharmaceutical cannabinoids in reducing or treating MH and SUD among people of any age. The Cochrane risk of bias tool 2.0 will be used to assess bias, while the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) tool will be used to assess the quality of evidence for each outcome. Study findings will be disseminated through published manuscripts, conferences, and health policy guidelines. Systematic review registration PROSPERO CRD42023392718.https://doi.org/10.1186/s13643-024-02657-3 |
| spellingShingle | Jack Wilson Andrew Langcake Zachary Bryant Tom P. Freeman Janni Leung Gary C. K. Chan Amir Englund Myfanwy Graham Emily Stockings The safety and efficacy of cannabinoids for the treatment of mental health and substance use disorders: protocol for a systematic review and meta-analysis Systematic Reviews |
| title | The safety and efficacy of cannabinoids for the treatment of mental health and substance use disorders: protocol for a systematic review and meta-analysis |
| title_full | The safety and efficacy of cannabinoids for the treatment of mental health and substance use disorders: protocol for a systematic review and meta-analysis |
| title_fullStr | The safety and efficacy of cannabinoids for the treatment of mental health and substance use disorders: protocol for a systematic review and meta-analysis |
| title_full_unstemmed | The safety and efficacy of cannabinoids for the treatment of mental health and substance use disorders: protocol for a systematic review and meta-analysis |
| title_short | The safety and efficacy of cannabinoids for the treatment of mental health and substance use disorders: protocol for a systematic review and meta-analysis |
| title_sort | safety and efficacy of cannabinoids for the treatment of mental health and substance use disorders protocol for a systematic review and meta analysis |
| url | https://doi.org/10.1186/s13643-024-02657-3 |
| work_keys_str_mv | AT jackwilson thesafetyandefficacyofcannabinoidsforthetreatmentofmentalhealthandsubstanceusedisordersprotocolforasystematicreviewandmetaanalysis AT andrewlangcake thesafetyandefficacyofcannabinoidsforthetreatmentofmentalhealthandsubstanceusedisordersprotocolforasystematicreviewandmetaanalysis AT zacharybryant thesafetyandefficacyofcannabinoidsforthetreatmentofmentalhealthandsubstanceusedisordersprotocolforasystematicreviewandmetaanalysis AT tompfreeman thesafetyandefficacyofcannabinoidsforthetreatmentofmentalhealthandsubstanceusedisordersprotocolforasystematicreviewandmetaanalysis AT jannileung thesafetyandefficacyofcannabinoidsforthetreatmentofmentalhealthandsubstanceusedisordersprotocolforasystematicreviewandmetaanalysis AT garyckchan thesafetyandefficacyofcannabinoidsforthetreatmentofmentalhealthandsubstanceusedisordersprotocolforasystematicreviewandmetaanalysis AT amirenglund thesafetyandefficacyofcannabinoidsforthetreatmentofmentalhealthandsubstanceusedisordersprotocolforasystematicreviewandmetaanalysis AT myfanwygraham thesafetyandefficacyofcannabinoidsforthetreatmentofmentalhealthandsubstanceusedisordersprotocolforasystematicreviewandmetaanalysis AT emilystockings thesafetyandefficacyofcannabinoidsforthetreatmentofmentalhealthandsubstanceusedisordersprotocolforasystematicreviewandmetaanalysis AT jackwilson safetyandefficacyofcannabinoidsforthetreatmentofmentalhealthandsubstanceusedisordersprotocolforasystematicreviewandmetaanalysis AT andrewlangcake safetyandefficacyofcannabinoidsforthetreatmentofmentalhealthandsubstanceusedisordersprotocolforasystematicreviewandmetaanalysis AT zacharybryant safetyandefficacyofcannabinoidsforthetreatmentofmentalhealthandsubstanceusedisordersprotocolforasystematicreviewandmetaanalysis AT tompfreeman safetyandefficacyofcannabinoidsforthetreatmentofmentalhealthandsubstanceusedisordersprotocolforasystematicreviewandmetaanalysis AT jannileung safetyandefficacyofcannabinoidsforthetreatmentofmentalhealthandsubstanceusedisordersprotocolforasystematicreviewandmetaanalysis AT garyckchan safetyandefficacyofcannabinoidsforthetreatmentofmentalhealthandsubstanceusedisordersprotocolforasystematicreviewandmetaanalysis AT amirenglund safetyandefficacyofcannabinoidsforthetreatmentofmentalhealthandsubstanceusedisordersprotocolforasystematicreviewandmetaanalysis AT myfanwygraham safetyandefficacyofcannabinoidsforthetreatmentofmentalhealthandsubstanceusedisordersprotocolforasystematicreviewandmetaanalysis AT emilystockings safetyandefficacyofcannabinoidsforthetreatmentofmentalhealthandsubstanceusedisordersprotocolforasystematicreviewandmetaanalysis |